The study aims to collect data on the diagnosis, treatment and effects of neuroblastomas and ganglioneuroblastomas from patients in 29 different countries in order to generate new scientific findings.
SIOPEN (the European neuroblastoma research group) in Austria is responsible for the international implementation of the study (sponsor). The Swiss Paediatric Oncology Group (SPOG) is responsible for performing the study in Switzerland (sponsor’s representative).
Background
Neuroblastoma and ganglioneuroblastoma are malignant tumours of the nervous system. They are among the most common forms of cancer in children and adolescents, and generally affect children under six years of age. The course of the disease varies widely: some cases are very aggressive, while other tumours are less malignant and regress spontaneously. As a result, the chances of recovery also vary significantly. Each year, 15-20 children and adolescents in Switzerland are affected by this disease and can take part in the study.
Why does the study need to be done?
The study aims to collect data on the diagnosis, treatment and effects of these diseases from patients in 29 different countries in order to generate new scientific findings. This work should result in a greater understanding of why these diseases develop and how their treatment can be improved in the future. In addition, the patients’ samples are to be stored in a virtual biobank for future research purposes.
In short
-
Data and samples relating to diagnosis, treatment and effects in patients with neuroblastoma are being collected for SIOPEN BIOPORTAL.
-
In patients with neuroblastoma, the course of the disease and the chances of recovery vary widely. The aim of this study is to gain a better understanding of this disease.
-
The cooperation and exchange between the scientists are expected to generate new scientific findings. This work should result in a greater understanding of why these diseases develop and how their treatment can be improved in future.
